Table 3.
Aspirin use | Men (HPFS) | Women (NHS) | Combined | ||||
---|---|---|---|---|---|---|---|
| |||||||
Cases | Person-Years | HR (95% CI)a | Cases | Person-Years | HR (95% CI)a | HR (95% CI)b | |
Cumulative average 325-mg tablets per week | |||||||
N | 72 | 319,474 | 193 | 1,678,032 | |||
| |||||||
Non-users | 19 | 73,701 | 1.00 (ref) | 30 | 369,337 | 1.00 (ref) | 1.00 (ref) |
| |||||||
<2 | 29 | 133,637 | 0.79 (0.44–1.42) | 75 | 609,143 | 0.99 (0.63–1.54) | 0.92 (0.66–1.30) |
| |||||||
2–<5 | 21 | 77,289 | 0.88 (0.47–1.65) | 56 | 351,847 | 1.13 (0.71–1.79) | 1.04 (0.72–1.50) |
| |||||||
≥5 | 3 | 34,847 | 0.28 (0.08–0.95) | 32 | 347,705 | 0.71 (0.43–1.18) | 0.61 (0.39–0.94) |
| |||||||
P-trend=0.11c | P-trend=0.22c | P-trend=0.06c | |||||
Continuous duration of regular use, years | |||||||
N | 132 | 664,264 | 196 | 1,731,194 | |||
| |||||||
Non-users | 52 | 256,203 | 1.00 (ref) | 30 | 369,337 | 1.00 (ref) | 1.00 (ref) |
| |||||||
≤5 | 55 | 269,879 | 0.77 (0.53–1.14) | 94 | 867,731 | 0.92 (0.60–1.39) | 0.80 (0.61–1.06) |
| |||||||
6–10 | 19 | 99,134 | 0.65 (0.38–1.10) | 44 | 293,653 | 1.32 (0.83–2.11) | 0.97 (0.69–1.35) |
| |||||||
≥11 | 6 | 39,047 | 0.42 (0.18–0.98) | 28 | 200,472 | 0.81 (0.48–1.37) | 0.63 (0.41–0.95) |
| |||||||
P-trend=0.02c | P-trend=0.96c | P-trend=0.17c |
HRs and 95% CIs were computed in Cox proportional hazard models that stratified on age in months and adjusted for current BMI in kg/m2.
Cohort-combined Cox proportional hazard models were stratified on age in months and controlled for BMI (kg/m2) and cohort (gender).
For the trend tests, cumulative average tablets/week or continuous duration of regular aspirin use was modeled as an ordinal variable using the mid-point of each category of the respective variable in Cox proportional hazard models stratified by age in months and adjusted for the co-variables indicated.
Abbreviations: HPFS, Health Professionals Follow-up Study; NHS, Nurses’ Health Study; HR, hazard ratio; CI, confidence interval; ref, reference category